What is it about?
The study evaluates whether historical pharmaceutical assay results, arranged by production-lot order, can predict the assay result of a future lot. It compares forecasts from the original assay values with forecasts after a Box-Cox transformation. The dataset contained 199 valid lots, with 179 used for model development and the final 20 reserved for validation.
Featured Image
Photo by Melany @ tuinfosalud.com on Unsplash
Why is it important?
A reliable forecasting model could complement routine quality monitoring by: identifying unexpected assay movement earlier; supporting proactive laboratory and manufacturing investigations; providing an objective estimate of the expected next-lot result; distinguishing ordinary assay variation from potentially unusual behavior. The model must not replace product specifications, release testing, stability studies, continued process verification, or formal quality risk management.
Perspectives
The study presents a useful proof of concept for lot-sequence monitoring. Its strongest feature is its cautious interpretation: it forecasts the next position in a production-lot sequence, not chemical stability over calendar time.
Independent Researcher & Consultant Mostafa Essam Eissa
Read the Original
This page is a summary of: ARIMA modeling for sequential pharmaceutical assay monitoring acrossproduction lots: Raw and Box-Cox sensitivity analyses, Bangladesh Journal of Scientific and Industrial Research, September 2026, Bangladesh Journals Online (BanglaJOL),
DOI: 10.3329/bjsir.v61i3.91215.
You can read the full text:
Contributors
The following have contributed to this page
